Tarsus Pharmaceuticals, Inc.
TARS
$58.85
$2.243.96%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 31.05% | 17.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 31.05% | 17.96% | |||
| Cost of Revenue | 11.27% | -10.00% | |||
| Gross Profit | 37.66% | 31.62% | |||
| SG&A Expenses | 21.20% | 23.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.34% | 15.18% | |||
| Operating Income | 15.59% | -7.61% | |||
| Income Before Tax | 19.03% | -8.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.03% | -8.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.03% | -8.68% | |||
| EBIT | 15.59% | -7.61% | |||
| EBITDA | 15.84% | -7.63% | |||
| EPS Basic | 24.78% | -6.51% | |||
| Normalized Basic EPS | 28.53% | -27.13% | |||
| EPS Diluted | 24.78% | -6.51% | |||
| Normalized Diluted EPS | 28.53% | -27.13% | |||
| Average Basic Shares Outstanding | 7.66% | 2.03% | |||
| Average Diluted Shares Outstanding | 7.66% | 2.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||